As resistance to standard antibiotics grows, RedHill's H. pylori regimen secures FDA approval

Natalie Grover

Reporter

In 2017, the WHO designated clarithromycin-resistant H. pylori, a bacterial infection that affects more than half of the global population, a high priority for antibiotic …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As resistance to standard antibiotics grows, RedHill's H. pylori regimen secures FDA approval

Natalie Grover

Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

FDA says Ozempic, Wegovy shortage is over

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Pfizer ends rollout of Beqvez, putting another dent in hemophilia gene therapy field

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

As re­sis­tance to stan­dard an­tibi­otics grows, Red­Hill's H. py­lori reg­i­men se­cures FDA ap­proval

Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

As resistance to standard antibiotics grows, RedHill's H. pylori regimen secures FDA approval